1. Scrip
  2. >>Business

Regeneron’s Eylea Faces Pressure, But Pipeline Shows Strength

 
• By Alaric DeArment

The drug maker’s top-selling Eylea franchise faces market challenges as biosimilars roll out, but Regeneron is confident about a pipeline that includes multiple significant catalysts in 2025.

(Shutterstock)

Regeneron Pharmaceuticals expects to see downward pressure on the 2mg version of Eylea (aflibercept) continue after 2024, but demand for the VEGF inhibitor has remained high despite the introduction of the first aflibercept biosimilar.

The Tarrytown, NY-based drug maker announced its fourth-quarter and full-year 2024 earnings on 4 February, reporting that quarterly revenues increased by 10% to $3

Key Takeaways
  • Regeneron reported that its fourth-quarter sales grew 10% to $3.79bn, while full-year sales for 2024 grew 8% to $14.2bn.
  • Libtayo, the company’s PD-1 checkpoint inhibitor, crossed the blockbuster threshold, with full year 2024 sales of $1.22bn

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.